Trastuzumab emtansine improves outcomes in residual HER2-positive breast cancer
1. In this randomized controlled trial, adjuvant trastuzumab emtansine (T-DM1) reduced invasive disease events in patients with residual human epidermal ...
Tag: trastuzumab emtansine
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
1. Invasive disease-free survival occurred in 19.7% of the T-DM1 group and 32.2% in the trastuzumab group, with an HR ...
#VisualAbstract: Increased Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer Relative to Trastuzumab Alone
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Trastuzumab deruxtecan superior to physician’s choice treatment in patients with metastatic HER2-positive breast cancer
1. Progression-free survival was greater in the trastuzumab group compared to standard care (17.8 months vs. 6.9 months). 2. Drug-related ...
Trastuzumab deruxtecan associated with lower risk of metastatic breast cancer progression
1. Compared to trastuzumab emtansine, trastuzumab deruxtecan is associated with a lower risk of disease progression or death in patients ...
#VisualAbstract: Trastuzumab emtansine monotherapy is noninferior to standard neoadjuvant therapy for ERBB2+ breast cancer
Click to read the study in JAMA Oncology.
#VisualAbstract: Neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen shows high cost-effectiveness for ERBB2-positive breast cancer
Click to read the study in JAMA Network Open